Clinical Trial Update: Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating Iscador P (mistletoe) immunotherapy for recurrent osteosarcoma and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Iscador P (Mistletoe) Immunotherapy (Iscador P)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Osteogenic Sarcoma Recurrent | Phase 2 | Status: RECRUITING